Micrus reports on aneurysm trial for MicroCoil:
This article was originally published in Clinica
Executive Summary
Micrus has presented trial data on 120 intracranial aneurysms embolised using its minimally invasive ACT MicroCoil system. The product, which employs a heat resistive detachment system, was reported to be quick, effective and reliable in treating intracerebral aneurysms - principally wide neck lesions. The MicroCoil was used to treat patients with a wide variety of aneurysms and procedures done in both the anterior and posterior circulation of the brain were successful, said the Mountain View, California firm. The MicroCoil system gained US FDA and CE-mark approvals for sale last year.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.